This comprehensive case study explores Kymanox’s approach to emergency-use combination product development through integrated Chemistry Manufacturing Controls (CMC), clinical support, and regulatory strategy. Our team of Subject Matter Experts (SMEs) collaborated closely with virtual pharmaceutical stakeholders to implement measurable improvements across formulation optimization, process controls, clinical trial material manufacturing, regulatory submissions, and quality system implementation for life-saving emergency-use therapies.
CHALLENGE
SOLUTION
RESULTS
- Small-cap virtual pharmaceutical client required comprehensive CMC, clinical, and regulatory support for emergency-use combination product development and approval.
- Formulation optimization, process controls, and packaging strategies essential ensuring product stability, efficacy, and shelf-life meeting emergency-use requirements.
- Clinical Trial Material (CTM) manufacturing facilitation and regulatory submission support critical for FDA approval pathway and timely market access.
- Scalable Quality Management System (QMS) and commercial manufacturing readiness needed supporting transition from development through commercial production.
- Addressed critical preservative degradation and impurity generation issues enhancing process controls ensuring long-term product stability and regulatory compliance.
- Provided regulatory-aligned bioequivalence reviews and conducted comprehensive device reliability assessments confirming suitability for emergency-use applications.
- Drafted complete New Drug Application (NDA) submission, facilitated strategic FDA meetings, and performed Human Factors (HF) assessments ensuring device usability and safety.
- Managed seamless technology transfer to commercial manufacturing facility establishing scalable production processes and quality systems.
- Implemented electronic Quality Management System (eQMS) establishing compliant infrastructure supporting commercial operations and ongoing regulatory compliance.
- Coordinated cross-functional activities across CMC, clinical, regulatory, and quality disciplines ensuring integrated development approach.
- Successfully guided client through critical regulatory and development milestones achieving FDA approval pathway for emergency-use combination product.
- Ensured clinical and commercial readiness of emergency-use combination product through comprehensive development support and quality system establishment.
- Demonstrated exceptional flexibility and scalability particularly during intensive NDA drafting phase adapting resources to meet aggressive submission timelines.
- Established sustainable commercial manufacturing capability and quality infrastructure supporting product launch and ongoing compliance.
- Delivered life-saving therapy to market through integrated regulatory strategy and technical excellence.